Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Stanford has developed a protocol that involves giving such highly sensitized patients a high dose of intravenous immunoglobulin, or IVIG and other medications. The IVIG infusions, which may be repeated over several months, lower the number of organ-rejecting antibodies in patients awaiting transplants. Hospital researchers have also developed a new assays system that allow us to see specifically what antibodies a patient has, and to predict which ones are going to go away with IVIG infusions.
Our goal with all these tests, treatments and technologies is not only to get more patients to transplantation, but more importantly, to create more successful outcomes for those patients.